The article discusses classifications of medicines for Antioxidants gene and cell therapy.Data on medicinal products registered in Russia, as well as in the European Union countries, Great Britain, USA, and Japan is presented.The limitations on using such medicinal products were considered, including their high utilitarian cost and high risk of adverse VCR Idler Assembly events.The potential for increasing clinical efficacy and economic feasibility of advanced therapies (pediatrics included) has been analyzed.